Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel Stallard

Showing results (141-150 of 153) with videos related to

Pageof 16
Sort By:
Trials|November 8, 2018
DELTA<sup>2</sup> guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trialJonathan A Cook, Steven A Julious, William Sones, et al.
Health Technology Assessment (Winchester, England)|October 30, 2019
Practical help for specifying the target difference in sample size calculations for RCTs: the DELTA<sup>2</sup> five-stage study, including a workshopJonathan A Cook, Steven A Julious, William Sones, et al.
The Lancet. Diabetes & Endocrinology|June 27, 2024
Early pregnancy HbA<sub>1c</sub> as the first screening test for gestational diabetes: results from three prospective cohortsPonnusamy Saravanan, Mohan Deepa, Zain Ahmed, et al.
BMJ (Clinical Research Ed.)|December 19, 2018
DELTA<sup>2</sup> guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trialJonathan A Cook, Steven A Julious, William Sones, et al.
The New England Journal of Medicine|July 19, 2018
A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac ArrestGavin D Perkins, Chen Ji, Charles D Deakin, et al.
BMJ Open|September 1, 2018
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosisPeter Connick, Floriana De Angelis, Richard A Parker, et al.
Resuscitation|September 22, 2016
Pre-hospital Assessment of the Role of Adrenaline: Measuring the Effectiveness of Drug administration In Cardiac arrest (PARAMEDIC-2): Trial protocolGavin D Perkins, Tom Quinn, Charles D Deakin, et al.
The Lancet. Neurology|January 26, 2020
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trialJeremy Chataway, Floriana De Angelis, Peter Connick, et al.
The British Journal of Radiology|January 24, 2024
Evidence-informed recommendations on managing breast screening atypia: perspectives from an expert panel consensus meeting reviewing results from the Sloane atypia projectKaroline Freeman, Alice Mansbridge, Hilary Stobart, et al.
The Lancet. Neurology|September 22, 2024
Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomised, adaptive platform trialSuvankar Pal, Jeremy Chataway, Robert Swingler, et al.
Pageof 16

Showing results (141-150 of 153) with videos related to

Sort By:
Pageof 16
Trials|November 8, 2018
DELTA<sup>2</sup> guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trialJonathan A Cook, Steven A Julious, William Sones, et al.
Health Technology Assessment (Winchester, England)|October 30, 2019
Practical help for specifying the target difference in sample size calculations for RCTs: the DELTA<sup>2</sup> five-stage study, including a workshopJonathan A Cook, Steven A Julious, William Sones, et al.
The Lancet. Diabetes & Endocrinology|June 27, 2024
Early pregnancy HbA<sub>1c</sub> as the first screening test for gestational diabetes: results from three prospective cohortsPonnusamy Saravanan, Mohan Deepa, Zain Ahmed, et al.
BMJ (Clinical Research Ed.)|December 19, 2018
DELTA<sup>2</sup> guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trialJonathan A Cook, Steven A Julious, William Sones, et al.
The New England Journal of Medicine|July 19, 2018
A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac ArrestGavin D Perkins, Chen Ji, Charles D Deakin, et al.
BMJ Open|September 1, 2018
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosisPeter Connick, Floriana De Angelis, Richard A Parker, et al.
Resuscitation|September 22, 2016
Pre-hospital Assessment of the Role of Adrenaline: Measuring the Effectiveness of Drug administration In Cardiac arrest (PARAMEDIC-2): Trial protocolGavin D Perkins, Tom Quinn, Charles D Deakin, et al.
The Lancet. Neurology|January 26, 2020
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trialJeremy Chataway, Floriana De Angelis, Peter Connick, et al.
The British Journal of Radiology|January 24, 2024
Evidence-informed recommendations on managing breast screening atypia: perspectives from an expert panel consensus meeting reviewing results from the Sloane atypia projectKaroline Freeman, Alice Mansbridge, Hilary Stobart, et al.
The Lancet. Neurology|September 22, 2024
Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomised, adaptive platform trialSuvankar Pal, Jeremy Chataway, Robert Swingler, et al.
Pageof 16